Alector Receives Upgrade from BTIG Research Amid Mixed Analyst Ratings

Alector (NASDAQ:ALEC) has been upgraded from a neutral rating to a buy rating by BTIG Research. This change, announced in a report released on Tuesday, establishes a price target of $6.00 for the biotechnology company’s shares. The upgrade comes amid a backdrop of varied evaluations from other analysts in recent weeks.

On January 8, 2024, Morgan Stanley reaffirmed its “underweight” rating for Alector, indicating a cautious outlook for the stock. Subsequently, on January 21, Weiss Ratings issued a “sell (d-)” rating, suggesting further concerns about the company’s performance. Adding to the mixed reviews, Wall Street Zen downgraded Alector from a “hold” rating to a “sell” on March 1, 2024.

Currently, a total of two equity research analysts have issued a buy rating for Alector. In contrast, four analysts have assigned a hold rating, and two have categorized the stock as a sell. According to data from MarketBeat, Alector holds a consensus rating of “Hold” with an average price target of $4.17.

Quarterly Earnings Reflect Positive Surprises

Alector recently reported its quarterly earnings on February 25, 2024, showcasing a surprise that surpassed analyst expectations. The company announced an earnings per share (EPS) of ($0.34), exceeding the consensus estimate of ($0.39) by $0.05. Revenue for the quarter reached $6.24 million, significantly higher than the anticipated $1.78 million. Despite these positive figures, Alector reported a negative net margin of 679.16% and a negative return on equity of 224.96%.

Looking ahead, analysts predict that Alector will post an EPS of ($1.88) for the current fiscal year, indicating ongoing challenges as the company works to establish a stronger financial footing.

Institutional Investors Increasing Holdings

In recent months, several institutional investors and hedge funds have adjusted their stakes in Alector. Virtu Financial LLC acquired a new position in Alector during the fourth quarter, investing approximately $34,000. Invesco Ltd. raised its holdings by 45.3%, resulting in ownership of 279,468 shares valued at $436,000 after acquiring an additional 87,157 shares.

Mackenzie Financial Corp increased its stake by 132.7% in the same quarter, holding 660,168 shares valued at $1,001,000 after adding 376,456 shares. XTX Topco Ltd saw a significant increase of 501.8% in its investment, owning 592,839 shares worth $925,000 following the purchase of an additional 494,326 shares. Lastly, Ikarian Capital LLC expanded its stake by 174.0%, now owning 2,082,606 shares valued at $3,249,000.

Institutional investors collectively own 85.83% of Alector’s stock, indicating strong interest in the company’s potential despite the mixed ratings from analysts.

Alector, headquartered in South San Francisco, California, is a clinical-stage biotechnology firm established in 2013. The company specializes in developing immuno-neurology therapies aimed at treating neurodegenerative disorders by targeting the innate immune system. Alector’s pipeline includes several product candidates in various stages of development, with lead programs AL001 and AL002 focused on frontotemporal dementia and Alzheimer’s disease.

As Alector navigates these challenges and opportunities, investors and analysts will be closely monitoring its performance and strategic developments in the biotech sector.